PMGC Holdings Inc(ELAB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:20 PM ET (Korea 9/12 05:20)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1815.13 | Insider Own | - | Shs Outstand | 0.8M | Perf Week | -13.58% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.8M | Perf Month | -49.78% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | - | Inst Own | 3.29% | Short Float | 3.14% | Perf Quarter | -71.03% |
| Income | -0.01B | P/S | 1.42 | EPS this Y | - | Inst Trans | - | Short Ratio | 0.1 | Perf Half Y | -89.73% |
| Sales | 0.00B | P/B | 0.17 | EPS next 5Y | - | ROA | -59.06% | Short Interest | 0.03M | Perf YTD | -98.73% |
| Book/sh | 27.2 | P/C | 0.19 | EPS past 3/5Y | 74.26% 15.55% | ROE | -105.22% | 52W High | -99.83% ($2671.20) | Perf Year | -99.61% |
| Cash/sh | 23.23 | P/FCF | - | Sales past 3/5Y | -8.34% - | ROIC | -63.6% | 52W Low | -0.24% ($4.53) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 99.47% | Gross Margin | 10.31% | Volatility(W/M) | 6.86% 11.95% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | -0.35 | Sales Y/Y TTM | - | Oper. Margin | -477.02% | ATR (14) | 0.63 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.3 | EPS Q/Q | 98.41% | Profit Margin | -522.97% | RSI (14) | 25.16 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.36 | Sales Q/Q | - | SMA20 | -23.54% ($5.91) | Beta | -0.41 | Target Price | - |
| Payout | - | Debt/Eq | 0.85 | Earnings | 2026/3/30 | SMA50 | -46.44% ($8.44) | Rel Volume | 0.04 | Prev Close | $4.6 |
| Employees | 34 | LT Debt/Eq | 0.27 | EPS/Sales Surpr. | - | SMA200 | -97.18% ($160.28) | Avg Volume(3M) | 0.25M | Price | $4.52 |
| IPO | 2023/11/21 | Option/Short | No/Yes | Trades | 252 | Volume | 11,102 | Change | -1.74% |
Company
ELAB is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 (PMGC Holdings) is a US small-cap diversified holding company spanning biotech, research, finance, and precision manufacturing. Its core subsidiary, Northstrive Biosciences, is developing EL-22, an oral probiotic designed to prevent muscle loss during GLP-1 obesity treatment, while the company as a whole is simultaneously pursuing the expansion of its business portfolio through mergers and acquisitions.
Over the past 1 year, on the lower side
100% below its 1-year high.
ELAB has weak earning power
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 3.3%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $4M.
ELAB $4M PER -
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is ELAB?
ELAB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ELAB?
The market cap of ELAB is approximately $4M, ranking 5,763 within its sector.
What is the 52-week high and low for ELAB?
ELAB has recorded a 52-week high of $2671.20 and a low of $4.53.
